Le Lézard
Classified in: Health, Business
Subjects: NPT, CHI, FOR, SRI

The END Fund Announces the Deworming Innovation Fund in Four African Countries on the Inaugural World NTD Day


NEW YORK, Jan. 30, 2020 /PRNewswire/ -- In recognition of the first-ever World NTD Day, the END Fund is bringing together private and public sector stakeholders to imagine a world free from diseases caused by parasitic worms that have held back human progress for millennia.

Deworming Innovation Fund, An Audacious Global Health Initiative

Today, the END Fund announces its Audacious project - the Deworming Innovation Fund - in four strategic countries: Ethiopia, Kenya, Rwanda, and Zimbabwe.

In April 2019, The Audacious Project announced its support of the END Fund and seven other organizations. The Audacious Project is a collaborative funding initiative between TED and leading nonprofits that convenes funders and social entrepreneurs in order to scale solutions to the world's most urgent challenges. By facilitating initial funding for the Deworming Innovation Fund, The Audacious Project has helped to catalyze additional commitments.

Neglected tropical diseases (NTDs) are a group of parasitic and bacterial infectious diseases affecting more than 1.7 billion of the world's population, with about 40% of this burden concentrated in Africa. Two of the most common NTDs are intestinal worms and schistosomiasis, both of which are parasitic worm infections. Treatments for these diseases, commonly known as deworming, reduce stunted growth in children and improve food and vitamin absorption. Studies have shown that children who are dewormed are 25% more likely to attend school, and adults are able to increase their earnings by 20%. Moreover, deworming also improves labor productivity and long-term economic gains.  

Slated to run through 2025, the Deworming Innovation Fund aims to accelerate progress towards tackling parasitic worm infections that affect more than 40 million children in Ethiopia, Rwanda, Zimbabwe, and Kenya. The END Fund will leverage drug donations from key pharmaceutical companies and coordinate with governments and partners to create robust delivery systems. Over the next five years, people at risk of intestinal worms and schistosomiasis in these four strategic countries will benefit from life-changing deworming treatment. Thus, ensuring that nobody is left behind and that at-risk demographics often overlooked in treatment campaigns, like women of reproductive age and children who are not yet in school, are reached.

"With initial funding raised through The Audacious Project, the END Fund garnered additional support for the Deworming Innovation Fund, which enables us to accelerate progress even faster than we had envisioned," said CEO Ellen Agler. "This groundbreaking capital allows us to reduce the burden of intestinal worms and schistosomiasis in the four countries, and invest in innovative approaches to treatment, prevention, and sustainability," said Agler.

In these four countries, local and national leaders have made trailblazing commitments to their national deworming programs. The generous and unwavering level of support to end NTDs continues to provide an opportunity to scale up proven approaches, trial new innovative approaches, and foster increased levels of community partnership. Through the Deworming Innovation Fund, the quality of life for millions can be improved because of the significant improvement to mental, physical, and social health. The END Fund is proud to stand with other global change-makers on this World NTD Day to ensure that these diseases get the necessary attention and investment that they deserve.

Anchor funding for this initiative has been committed through a collaboration of Audacious Project partners including The ELMA Foundation, Delta Philanthropies, Sir Christopher Hohn (administered via the Children's Investment Fund Foundation), Rosamund Zander and Hansjörg Wyss for the Wyss Medical Foundation, and Virgin Unite.

ABOUT the END FUND

The END Fund is the only private philanthropic initiative solely dedicated to ending the five most common neglected tropical diseases (NTDs), which affect more than 1.7 billion people globally. It efficiently puts private capital to work, advocating for NTD programs that are innovative, integrated, and cost-effective. It facilitates strong partnerships with the private sector and has supported national disease control programs in 30 countries.

Since its founding in 2012, with its partners, the END Fund has provided over 740 million donated treatments worth over $1 billion, over 12,900 surgeries for people suffering from the effects of the advanced stages of elephantiasis and trachoma, and trained more than 1.4 million people in NTD control and elimination efforts.

ABOUT THE AUDACIOUS PROJECT

Launched in April 2018, The Audacious Project is a collaborative funding initiative that's catalyzing social impact on a grand scale. Housed at TED, the nonprofit devoted to ideas worth spreading, and with support from leading social impact advisor The Bridgespan Group, The Audacious Project convenes funders and social entrepreneurs with the goal of supporting bold solutions to the world's most urgent challenges. The Audacious Project's funding collective is made up of respected organizations and individuals in philanthropy, including the Skoll Foundation, Virgin Unite, The Valhalla Charitable Foundation, ELMA Philanthropies and more. Each year The Audacious Project supports a new cohort. The 2019 recipients are Center for Policing Equity, Educate Girls, Institute for Protein Design, Salk Institute for Biological Studies, The END Fund, The Nature Conservancy, Thorn and Waterford's UPSTART project.

Media Contact: Tegan Mosugu - [email protected] / 626-502-7547

SOURCE The END Fund


These press releases may also interest you

at 22:33
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...



News published on and distributed by: